Dernièrement…

+70% pour @AmoebaNature alors que l'Agence américaine pour la protection de l'environnement a émis une pré-décision favorable après avoir évalué sa demande d'autorisation de 'Willaertia magna C2c Maky' https://www.boursorama.com/bourse/actualites/amoeba-vers-un-feu-vert-de-l-epa-pour-son-amibe-biocide-59c2a82b84038127133be13ae23167f9?symbol=1rPALMIB

$ALMIB #AMOEBA : L'US EPA en voie d’approuver le biocide d’Amoéba pour un usage dans les systèmes de refroidissement fermés https://t.news.calyptus.net/l2/7bPXwOEHO0/7007/2382335340.html?

📣 Communiqué de Presse : https://bit.ly/3zQlqqt
#Amoéba informe que l’US EPA a émis une pré-décision favorable pour commercialiser notre #biocide aux USA dans les systèmes de refroidissement fermés. Après 10 ans de #recherches, cette annonce légitime notre #savoirfaire unique💧

🏆 #Amoéba remporte l’Innovation Award
A l’occasion de la 3ème édition du #symposium @PBioprotech, les équipes d’Amoéba ont eu le plaisir de voir leur travail récompensé ! Un grand merci au jury pour avoir choisi notre #innovation #biocontrôle parmi les 11 candidats !

Appointment of Pierre Morgon to the Board of Directors

Amoéba appointed Pierre Morgon as non-voting Director with a view to proposing his candidacy as Director at the next General Meeting of Shareholders to be held in 2021. As a non-voting director, he will attend the next meetings of the Board of Directors in an advisory capacity, bringing his extensive experience and expertise to the Company.
Experiences and training
Pierre Morgon has over 30 years of experience in the global Life Sciences industry, especially specialty care, vaccines and immunotherapy, in management positions in multinational companies and as CEO of start-up companies.
He is a lecturer in several MBA programs and life sciences conferences, as well as at the Mass Challenge incubator in Switzerland where he also acts as a mentor for life sciences start-ups.
Currently, Pierre MORGON is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice-President International Business at CanSino Biologics.
He is also Chairman of the Boards of Directors of Theradiag, Eurocine Vaccines, MYCB1 and Health Technology Holding, as well as Non-Executive Director of the Boards of Directors of Vaccitech and Univercells.
He holds a doctorate in pharmacy, a master’s degree in business law and a MBA. He is also an alumnus of ESSEC, INSEAD and IMD.
“I would like to thank Fabrice Plasson for the confidence he has shown in me by asking me to join Amoeba’s Board of Directors. The company is in full expansion and the new applications of its technology in human health represent an exciting opportunity and challenge. I look forward to bringing my experience in life sciences, both in terms of development, partnerships and business development as well as governance” said Pierre MORGON.
“Pierre is a global reference in the field of vaccines and immunotherapies as well as in the entire value chain of the healthcare industry. It is a great pleasure to welcome him to our Board of Directors to benefit from his international vision (Chinese, European and American) in this sector. Pierre is also a recognized director of listed companies in Europe and an investment fund manager, with a perfect understanding of the challenges faced by companies such as Amoeba, which are undergoing strong acceleration,” said Fabrice Plasson, Chairman and CEO of Amoeba.